- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00722579
A Study of the Presillion Stent in de Novo Coronary Lesions (PRESILLION)
A Non-Randomized, Multi-Center, Single-Arm Safety Study of the Presillion Stent in de Novo Native Coronary Artery Lesions
The PRESILLION Study is a non-randomized, multi-center, single-arm study evaluating the safety of an approved Cobalt Chromium bare metal stent system for the treatment of ischemic heart disease attributable to a stenotic de novo lesion in a native coronary artery.
The study population will include 100 patients with up to two de novo native coronary artery lesions with a maximum lesion length of 30mm in a maximum of two major coronary arteries with reference vessel diameter >= 2.5mm and <= 4.0mm by visual estimation. Patients will be followed for 1 month and 6 month post-procedure for assessment of MACE and all other adverse events.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The PRESILLION Stent System is intended for use in patients with symptomatic ischemic heart disease attributable to stenotic de novo lesions of native coronary arteries with reference vessel diameter from 2.5 mm to 4.0 mm with a lesion length up to 30 mm that are amenable to percutaneous treatment with coronary stenting. The stent is intended as a permanent implanted device.
The primary objective of this study is to evaluate the safety of the PRESILLION Stent System in the treatment of de novo stenotic lesions in native coronary arteries. The primary safety measure is the composite of MACE up to one (1) month follow up. The MACE rate shall meet the performance goal for bare metal stents in order to show the safety of the device.
The protocol has been amended and data will be collected for a time point as close as possible to (but after) the 6 months post index procedure in a non-interventional and retrospective manner. The data point will contain exactly the same follow-up information as was collected during the 1 month follow-up.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Liège, Belgium, B-4000
- CHU de Liège
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient must be >= 18 years of age.
- Patient is eligible for percutaneous coronary intervention (PCI).
- Acceptable candidate for coronary artery bypass surgery (CABG).
- Female patients of childbearing potential must have a negative pregnancy test within 7 days prior to enrolment and utilize reliable birth control for trial duration.
- Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) or unstable angina pectoris (Braunwald Classification B&C, I-II-III) or patients with documented silent ischemia.
- Treatment of up to two de novo native coronary artery lesions in a maximum of two major coronary arteries.
- Target reference vessel diameter of both lesions must be >= 2.5mm and <= 4.0mm in diameter (visual estimate).
- Target lesion length must be <= 30mm and be covered by one study stent.
- Target lesion stenosis for both lesions is > 50% and < 100% (visual estimate).
- At least TIMI I coronary flow.
- Patient is willing to comply with the specified follow-up evaluation.
- Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee.
Exclusion Criteria:
- Recent myocardial infarction (either STEMI or non STEMI < 48 hours prior to planned index procedure).
- The patient has unstable angina classified as Braunwald A I-II-III.
- The patient has unprotected left main coronary artery disease (stenosis >50%).
- A significant (> 50%) stenosis proximal or distal to the target lesion.
- Angiographic evidence of thrombus within the target lesion.
- Heavily calcified lesion and/or calcified lesion, which cannot be successfully predilated and/or an excessively tortuous vessel which makes it unsuitable for stent delivery and deployment.
- Left ventricular ejection fraction <= 25%.
- Totally occluded lesion (TIMI 0 level).
- The patient has impaired renal function (creatinine 3.0mg/dL) at the time of treatment.
- The patient had a Cerebrovascular Accident (CVA) within the past 6 months.
- Prior stent within 10mm of target lesion.
- The target lesion is ostial in location (within 3.0mm of vessel origin).
- The target lesion involves a bifurcation with a diseased (>50% stenotic) branch vessel >= 2.0mm in diameter (or side branch requiring intervention of protection).
- The target lesion is located in a bypass graft. Note: stenting of lesions in bypassed native coronary arteries is allowed.
- Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix ®) and ticlopidine (Ticlid ®), heparin, cobalt chromium, contrast agent (that cannot be managed medically).
- The patient has any significant medical condition which in the investigator's opinion may interfere with the patient's optimal participation in the study.
- The patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the study endpoints.
- Intervention of another lesion within 30 days prior to, or is planned or highly probably to be performed 30 days after the index procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
The PRESILLION TM Coronary Stent is an L-605 cobalt chromium (CoCr) stent.
|
PTCA with bare-metal stent
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Composite of MACE which includes cardiac death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion revascularization (TLR).
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinically driven Target Lesion Revascularization (TLR) defined as repeat PCI or CABG to the target lesion.
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Clinically driven Target Vessel Revascularization (TVR) defined as repeat PCI or CABG to the target vessel.
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Target Vessel Failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vessel.
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Myocardial Infarction (MI).
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Major bleeding.
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Device success.
Time Frame: Post-procedure
|
Post-procedure
|
Lesion success.
Time Frame: Post-procedure
|
Post-procedure
|
Procedure success.
Time Frame: Post-procedure
|
Post-procedure
|
Incidence of acute and sub-acute stent thrombosis according the ARC definition.
Time Frame: 1-month and 6-months post-procedure
|
1-month and 6-months post-procedure
|
Stroke.
Time Frame: Post-procedure
|
Post-procedure
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: V. Legrand, MD, Phd, CHU de Liège
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EC08-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on PRESILLION cobalt chromium stent
-
Terumo Europe N.V.CompletedCoronary Artery Disease | Angioplasty, Transluminal, Percutaneous CoronarySpain, Germany, Serbia, France, Italy
-
Johnson and Johnson, S.A.CompletedCoronary ArteriosclerosisSpain, Portugal
-
Hospital Clinic of BarcelonaCompletedMyocardial Infarction | Infarction | Necrosis | Cardiovascular Diseases | Vascular Diseases | ST Elevation Myocardial Infarction | Heart DiseaseSpain, Italy, Netherlands
-
Spanish Society of CardiologyCompletedMyocardial InfarctionSpain, Italy, Netherlands
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
International Biomedical Systems S.p.A.UnknownCoronary Artery Disease | Angioplasty, Transluminal, Percutaneous Coronary | StentsGermany, Italy, Netherlands, Switzerland
-
Iwate Medical UniversityCompleted
-
NeodentNot yet recruitingMissing Teeth | Prosthesis Survival
-
Duk-Woo Park, MDCardioVascular Research Foundation, KoreaTerminatedPercutaneous Transluminal Coronary AngioplastyKorea, Republic of
-
Cairo UniversityUnknown